Leadopharma

Leadopharma, founded in 2016, is a biotechnology and pharmaceutical startup pioneering the future of pain, epilepsy, depression, and neurodegenerative treatment through innovative drug synthesis and advanced pharmacology research. The company has built a comprehensive pharmaceutical chemistry and ion channel drug R&D platform and a team capable of independently conducting drug synthesis, activity screening, and early safety pharmacology research for ion channel targets. In its latest financing round, Leadopharma secured a Series A investment on 07 August 2023 from a consortium of notable investors including Shanghai Healthcare Capital, Zhangke Lingyi Investment, Hongfeng Investment Management, and Hongke Baishi. With its focus on addressing critical unmet medical needs, Leadopharma is poised to make significant strides in the field of pharmaceutical research and development.